MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted DrugsIn vitroandIn vivo
Tóm tắt
The serine/threonine kinase Akt lies at a critical signaling node downstream of phosphatidylinositol-3-kinase and is important in promoting cell survival and inhibiting apoptosis. An Akt inhibitor may be particularly useful for cancers in which increased Akt signaling is associated with reduced sensitivity to cytotoxic agents or receptor tyrosine kinase inhibitors. We evaluated the effect of a novel allosteric Akt inhibitor, MK-2206, in combination with several anticancer agents. In vitro, MK-2206 synergistically inhibited cell proliferation of human cancer cell lines in combination with molecular targeted agents such as erlotinib (an epidermal growth factor receptor inhibitor) or lapatinib (a dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor). Complementary inhibition of erlotinib-insensitive Akt phosphorylation by MK-2206 was one mechanism of synergism, and a synergistic effect was found even in erlotinib-insensitive cell lines. MK-2206 also showed synergistic responses in combination with cytotoxic agents such as topoisomerase inhibitors (doxorubicin, camptothecin), antimetabolites (gemcitabine, 5-fluorouracil), anti-microtubule agents (docetaxel), and DNA cross-linkers (carboplatin) in lung NCI-H460 or ovarian A2780 tumor cells. The synergy with docetaxel depended on the treatment sequence; a schedule of MK-2206 dosed before docetaxel was not effective. MK-2206 suppressed the Akt phosphorylation that is induced by carboplatin and gemcitabine. In vivo, MK-2206 in combination with these agents exerted significantly more potent tumor inhibitory activities than each agent in the monotherapy setting. These findings suggest that Akt inhibition may augment the efficacy of existing cancer therapeutics; thus, MK-2206 is a promising agent to treat cancer patients who receive these cytotoxic and/or molecular targeted agents. Mol Cancer Ther; 9(7); 1956–67. ©2010 AACR.
Từ khóa
Tài liệu tham khảo
Bellacosa, 1991, A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region, Science, 254, 274
Burgering, 1995, Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction, Nature, 376, 599, 10.1038/376599a0
Carnero, 2008, The PTEN/PI3K/AKT signaling pathway in cancer, therapeutic implications, Curr Cancer Drug Targets, 8, 187, 10.2174/156800908784293659
Tokunaga, 2008, Deregulation of the Akt pathway in human cancer, Curr Cancer Drug Targets, 8, 27, 10.2174/156800908783497140
Maira, 2008, Class IA PI3 kinase: from their biological implication in human cancers to drug discovery, Expert Opin Ther Targets, 12, 223, 10.1517/14728222.12.2.223
Vivanco, 2002, The phosphatidylinositol 3-kinase AKT pathway in human cancer, Nat Rev Cancer, 2, 489, 10.1038/nrc839
Nogueira, 2008, Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis, Cancer Cell, 14, 427, 10.1016/j.ccr.2008.11.003
Pastukh, 2005, Contribution of the PI 3-kinase/Akt survival pathway toward osmotic preconditioning, Mol Cell Biochem, 269, 59, 10.1007/s11010-005-2536-z
West, 2002, Activation of the PI3K/Akt pathway and chemotherapeutic resistance, Drug Resist Updat, 5, 234, 10.1016/S1368-7646(02)00120-6
Winograd-Katz, 2006, Cisplatin induces PKB/Akt activation and p38 MAPK phosphorylation of the EGF receptor, Oncogene, 25, 7381, 10.1038/sj.onc.1209737
Liu, 2007, AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway, Cancer Res, 67, 6325, 10.1158/0008-5472.CAN-06-4261
Bellacosa, 2005, Activation of AKT kinases in cancer: implications for therapeutic targeting, Adv Cancer Res, 94, 29, 10.1016/S0065-230X(05)94002-5
Yan, 2006, Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner, Gynecol Oncol, 102, 348, 10.1016/j.ygyno.2005.12.033
Clark, 2002, Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells, Mol Cancer Ther, 1, 707
She, 2005, The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells, Cancer Cell, 8, 287, 10.1016/j.ccr.2005.09.006
Brognard, 2001, Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation, Cancer Res, 61, 3986
Dillon, 2007, The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer, Oncogene, 26, 1338, 10.1038/sj.onc.1210202
Jiang, 2008, PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochim Biophys Acta, 1784, 150, 10.1016/j.bbapap.2007.09.008
Lindsley, 2005, Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors, Bioorg Med Chem Lett, 15, 761, 10.1016/j.bmcl.2004.11.011
Barnett, 2005, Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors, Biochem J, 385, 399, 10.1042/BJ20041140
Defeo-Jones, 2005, Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members, Mol Cancer Ther, 4, 271, 10.1158/1535-7163.271.4.2
Yan, 2009, MK-2206: a potent oral allosteric AKT inhibitor, AACR Annual Meeting, Abstract Number: DDT01-1
Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enz Regul, 22, 27, 10.1016/0065-2571(84)90007-4
Ihle, 2009, Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance, Cancer Res, 69, 143, 10.1158/0008-5472.CAN-07-6656
She, 2008, Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling, PLoS ONE, 3, e3065, 10.1371/journal.pone.0003065
Thomson, 2005, Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition, Cancer Res, 65, 9455, 10.1158/0008-5472.CAN-05-1058
Konecny, 2006, Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells, Cancer Res, 66, 1630, 10.1158/0008-5472.CAN-05-1182
Pillay, 2009, The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases, Neoplasia, 11, 448, 10.1593/neo.09230
Sharma, 2007, Epidermal growth factor receptor mutations in lung cancer, Nat Rev Cancer, 7, 169, 10.1038/nrc2088
Gazdar, 2004, Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?, Trends Mol Med, 10, 481, 10.1016/j.molmed.2004.08.008
Yamasaki, 2007, Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt, Cancer Res, 67, 5779, 10.1158/0008-5472.CAN-06-3020
Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478
Chen, 2008, Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors, Clin Cancer Res, 14, 6730, 10.1158/1078-0432.CCR-08-0581
Tokunaga, 2006, Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients, Int J Cancer, 118, 284, 10.1002/ijc.21358
Buck, 2008, Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors, Cancer Res, 68, 8322, 10.1158/0008-5472.CAN-07-6720
Morgillo, 2006, Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib, Cancer Res, 66, 10100, 10.1158/0008-5472.CAN-06-1684
Engelman, 2008, Effective use of PI3K and MEK inhibitors to treat mutant K-Ras G12D and PIK3CA H1047R murine lung cancers, Nat Med, 14, 1351, 10.1038/nm.1890
Yu, 2008, Response and determinants of cancer cell susceptibility to PI3K inhibitors, Cancer Biol Ther, 7, 307, 10.4161/cbt.7.2.5334
Harima, 2001, Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy, Int J Oncol, 18, 493
O'Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925
Han, 2007, Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition, Oncogene, 26, 5655, 10.1038/sj.onc.1210343
Hövelmann, 2004, Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells, Brit J Cancer, 90, 2370, 10.1038/sj.bjc.6601876
Lee, 2008, Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin, Int J Cancer, 122, 2380, 10.1002/ijc.23371